T-Therapeutics raises $133M to advance bispecific therapies
TL;DR:
- T-Therapeutics announced a $133 million Series B on November 5, 2026.
- Advent Life Sciences and British Business Bank co-led the round.
- Seven existing investors returned for the financing.
- T-Therapeutics will use the capital to advance its bispecific therapies.
Summary
T-Therapeutics secured $133 million in a Series B round announced on November 5, 2026. Advent Life Sciences and British Business Bank co-led the deal, which included support from seven existing investors. The company will use the capital to advance its TCR-based bispecific therapies for patients.
The Bigger Picture
The headline tells you what happened. Discover the facts behind it, the forces at work, the connections that matter, and what comes next.
Why This Matters
The financing puts $133 million behind T-Therapeutics' TCR-based bispecific approach, with seven existing investors returning. That could give the company more capacity to develop its therapies, while repeat participation signals continued financial support. Neither establishes clinical success. For competing developers and life-sciences investors, the news points to a potentially better-resourced participant, not a validated therapeutic approach.
Where the Story Goes Next
- ScenarioWatch for disclosed development milestones that show whether the financing advances T-Therapeutics' TCR-based bispecific programs.